What are the Benefits of Zydus Cadila's Newly Approved ZyCov-D Vaccine

Zycov-D is developed by Zydus Cadila and it has been approved for emergency use for Covid-19 in India. India has already approved 5 vaccines and now ZyCov-D is also approved for emergency use in India. ZyCov-D has been tested and can be given to children and adults 12 years and above.

Zydus Cadila has approved Zycov-D vaccine for Phase III clinical trials under the Department of Biotebiotechnology by the Drug Controller General of India (DCGI) in Zydus Cadila. Cadila Healthcare will begin the Phase II trials of the vaccine candidate on August 6, 2021, as part of an adaptive multicentre dose increase in phase I / II using randomized, placebo-controlled methods. The company also confirmed that a second candidate vaccine, ZycoV-MV, targeting COVID-19, has completed pragmatic clinical trials in non-human primate immunogenicity studies and will be presented shortly. 

Key Pointers about ZyCov-D Vaccine:

• ZyCov-D is the world’s first Plasmid DNA Vaccine for Covid-19
• ZyCov-D Vaccine Will be administered in 3 doses
• The 3 doses will be taken as the first dose on day zero, then the second dose on the 28^th day, and then the third dose on 56^th
• ZyCov-D works against new variants of the Covid-19, as Claimed by Zydus Cadila.
• ZyCov-D works by using Virus’s genetic material and with that, it produces proteins that can help the immune system to fight the Covid-19 virus.
• Along with the adults, the adolescents of the age group of 12-18 years can take this vaccine
• Children with comorbidities will be given priority for those below the age of 18 years in the ZyCov-D vaccination drive, said the Chairman of the National Technical Advisory Group on Immunization.

Zydus Cadila's Zycov-D COVID-19 vaccine is the only DNA-based vaccine in the world that can be administered with a needle to minimize the chances of a reaction. The drug controller general on Friday granted the emergency approval for the vaccine developed by the company and made it the first vaccination in India to be given to adults over 12 years old.

The Zycov-D vaccine uses parts of the virus's genetic material (DNA and RNA) to make certain proteins that the immune system can recognize and respond to. The vaccine is administered in three doses: a second dose is administered on the 28th day after the first dose, a third on the 56th day after the second dose, and so on. Phase I trials with the vaccine candidate began on 15 July 2020 and continued until October 2020. It was tested on 48 healthy individuals aged 18 to 55, ranging from 28 days to three doses.

Read More Similar Blogs - https://healthcarenewsspot.blogspot.com/2021/08/how-is-rising-use-of-ai-and-iot.html